What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Gilead Sciences' financial results for the third quarter of 2024, which ended on September 30, 2024. It includes the press release containing these results.

Where can I find the detailed financial results?

The detailed financial results are provided in the press release, filed as Exhibit 99.1 to this 8-K report. You should refer to this exhibit for specific figures and commentary on performance.

What is the difference between GAAP and non-GAAP financial information mentioned?

GAAP (Generally Accepted Accounting Principles) are the standard accounting rules in the U.S. Non-GAAP financial measures are adjustments made by management to exclude certain items from GAAP results, which they believe provide a clearer view of ongoing operational performance. Gilead provides a reconciliation between these two sets of measures in its press release.

Is the financial information in this filing considered 'filed' under SEC rules?

No, the information in Item 2.02 and Item 9.01 of this Form 8-K, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to its liabilities. It also won't be automatically incorporated by reference into other SEC filings.

GILD 8-K: Earnings & Results

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on November 6, 2024, to report its financial results for the quarter ended September 30, 2024. The filing primarily consists of a press release announcing these results, which provides both GAAP and non-GAAP financial information. Investors should refer to the press release, filed as Exhibit 99.1, for detailed financial performance data, including comparisons and reconciliations between GAAP and non-GAAP metrics. The company emphasizes that its non-GAAP financial information is provided as a supplementary measure, useful for understanding operational performance and for internal management purposes. While management believes these non-GAAP measures offer valuable insights, they are not prepared under comprehensive accounting rules and may differ from how other companies define and calculate similar metrics. Investors are advised to consider this non-GAAP information alongside Gilead's official GAAP financial statements for a complete understanding.

Key Highlights

1Gilead Sciences announced its Q3 2024 financial results via an 8-K filing on November 6, 2024.
2The filing includes a press release (Exhibit 99.1) detailing the financial performance for the quarter ended September 30, 2024.
3Both GAAP and non-GAAP financial measures are presented in the press release.
4Gilead management uses non-GAAP financial information internally for operational and financial planning.
5Investors are encouraged to review the press release for a comprehensive understanding of the results.
6A reconciliation between GAAP and non-GAAP financial information is available on pages 10-12 of the press release.
7The information provided in this 8-K is furnished and not deemed 'filed' for Section 18 of the Exchange Act.

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Nov 6, 2024)

Summary

Key Highlights

Frequently Asked Questions